PER-003-16尚未招募未知
A 96-WEEK, PROSPECTIVE, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF MASITINIB 4.5 MG/KG/DAY VERSUS PLACEBO IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE OR RELAPSE-FREE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
AB Science,0 个研究点目标入组 0 人开始时间: 2016年6月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 75（—）
入选标准
- •1. Patient suffering from either primary progressive or secondary progressive multiple sclerosis without relapse within 2 years before inclusion according to the revised McDonald’s criteria
- •2. Patient with EDSS score of [2.0 to 6.0] inclusive at baseline
- •3. Patient who had an EDSS score progression ≥ 1 point within 2 years before inclusion
- •4. Patient with normal organ function defined as:
- • Absolute neutrophils count (ANC) ≥ 2 x 109/L
- • Hemoglobin ≥ 10 g/dL
- • Platelets (PTL) ≥ 100 x 109/L
- • AST/ALT ≤ 3 ULN
- • Bilirubin ≤ 1.5x ULN
- • Creatinine clearance > 60 mL/min (Cockcroft and Gault formula)
- • Albuminemia > 1 x LLN
- • Proteinuria < 30 mg/dL (1+) on dipstick; in case of the proteinuria ≥1+ on the dipstick 24 hours proteinuria must be < 1.5g/24 hours
- •5. Male or female patient aged between 18 and 75 years old, with a weight > 50 kg and BMI between 18 and 35 kg/m².
- •6. Female patient of childbearing potential (entering the study after a menstrual period and who have a negative pregnancy test), who agrees to use two highly effective methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake.
- •7. Male patients must use medically acceptable methods of contraception if your female partner is pregnant, from the time of the first administration of the study drug until three months following administration of the last dose of study drug.
排除标准
- •1. Patient suffering from a disease other than MS that would better explain the patient’s neurological clinical signs and symptoms and/or MRI lesions
- •2. Patient who had a major surgery within 2 weeks of study entry
- •3. Patient with life expectancy < 6 months
- •4. Patient with history of primary malignancy < 5 years, except treated basal cell skin cancer or cervical carcinoma in situ
- •5. Patient presenting with cardiac disorders defined by at least one of the following conditions:
- • Patient with recent cardiac history (within 6 months) of:
- •- Acute coronary syndrome
- •- Acute heart failure (class III or IV of the NYHA classification)
- •- Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- • Patient with cardiac failure class III or IV of the NYHA classification
- • Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- • Syncope without known aetiology within 3 months
- • Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
- •6. Patient with any severe and/or uncontrolled medical condition
- •7. Patient with a known diagnosis of human immunodeficiency virus (HIV) infection
- •8. Patient with known hepatitis B, hepatitis C or tuberculosis
- •9. Pregnant or nursing female
研究者
相似试验
进行中（未招募）
1 期
A phase 3 study to compare efficacy and safety of masitinib with placebo in the patients with primary progressive or secondary progressive multiple sclerosis without relapse.Patients with primary progressive or secondary progressive multiple sclerosis without relapseMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-000639-30-GRAB Science800
进行中（未招募）
1 期
A phase 3 study to compare efficacy and safety of masitinib with placebo in the patients with primary progressive or secondary progressive multiple sclerosis without relapse.Patients with primary progressive or secondary progressive multiple sclerosis without relapseMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-000639-30-DEAB Science800
进行中（未招募）
1 期
A phase 3 study to compare efficacy and safety of masitinib with placebo in the patients with primary progressive or secondary progressive multiple sclerosis without relapse.Patients with primary progressive or secondary progressive multiple sclerosis without relapseMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-000639-30-ESAB Science800
进行中（未招募）
3 期
2-parallel groups, Phase 3 study to compare efficacy and safety of masitinib versus placebo in the treatment of primary progressive or relapse-free secondary progressive multiple sclerosisCTRI/2016/09/007268AB Science1
进行中（未招募）
不适用
A 96 weeks study to compare efficacy and safety of masitinib to placebo in the treatment of patients with primary progressiveor relapse free secondary progressive multiple sclerosisPrimary progressive or relapse-free secondary progressive multiple sclerosisMedDRA version: 16.0Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 16.0Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-021219-17-PLAB Science450